OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
Zhen Ruan, Yixuan Jiang, Honghao Shi, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 161-176
Closed Access | Times Cited: 7
Zhen Ruan, Yixuan Jiang, Honghao Shi, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 161-176
Closed Access | Times Cited: 7
Showing 7 citing articles:
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
David M. Williams, Barbara-Alex Alberts, Asem Sharaf, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 7, pp. 1639-1646
Open Access | Times Cited: 9
David M. Williams, Barbara-Alex Alberts, Asem Sharaf, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 7, pp. 1639-1646
Open Access | Times Cited: 9
Increased Role of Open Bibliographic Data in the Context of Restricted Access to Proprietary Information Systems
В. Н. Гуреев, Н. А. Мазов
Science management theory and practice (2023) Vol. 5, Iss. 2, pp. 49-76
Open Access | Times Cited: 13
В. Н. Гуреев, Н. А. Мазов
Science management theory and practice (2023) Vol. 5, Iss. 2, pp. 49-76
Open Access | Times Cited: 13
Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, et al.
Diabetes Research and Clinical Practice (2025), pp. 112086-112086
Closed Access
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, et al.
Diabetes Research and Clinical Practice (2025), pp. 112086-112086
Closed Access
Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population
E. Paleček, Margaret M. Kimzey, Jingwen Zhang, et al.
Journal of Investigative Medicine (2024)
Closed Access | Times Cited: 1
E. Paleček, Margaret M. Kimzey, Jingwen Zhang, et al.
Journal of Investigative Medicine (2024)
Closed Access | Times Cited: 1
Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study
Ying Hu, Xianwen Chen, Huimin Zou, et al.
Advances in Therapy (2024)
Closed Access | Times Cited: 1
Ying Hu, Xianwen Chen, Huimin Zou, et al.
Advances in Therapy (2024)
Closed Access | Times Cited: 1
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
María Dolores García de Lucas, Irene Caballero, José Carlos Fernández‐García, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
María Dolores García de Lucas, Irene Caballero, José Carlos Fernández‐García, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort
Jersy Cárdenas‐Salas, Roberto Miguel Sierra Poyatos, Bogdana Luiza Luca, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 12, pp. 108874-108874
Closed Access
Jersy Cárdenas‐Salas, Roberto Miguel Sierra Poyatos, Bogdana Luiza Luca, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 12, pp. 108874-108874
Closed Access
